MedTrace Logo

Convalescent Plasma Treatment in Severe 2009 H1N1 Infection

NCT01306773 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2011-03-02

No results posted yet for this study

Summary

Treatment of severe 2009 H1N1 infection with convalescent plasma will reduce mortality.

Conditions

Interventions

DRUG

H1N1 convalescent plasma and oseltamivir

Oseltamivir 75mg bid orally during ICU hospitalization + 500mL convalescent plasma containing \>= 1:160 of neutralizing antibody to Pandemic influenza A H1N1

DRUG

Oral Oseltamivir alone

Oral Oseltamivir 75mg bid during ICU hospitalization

Sponsors & Collaborators

  • The University of Hong Kong

    lead OTHER

Principal Investigators

  • Ivan FN HUNG, MD FRCP · The University of Hong Kong

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-12-31
Primary Completion
2010-12-31
Completion
2010-12-31

Countries

  • China

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01306773 on ClinicalTrials.gov